Online Data Instead Of Drug Retrials? - InformationWeek
Healthcare // Patient Tools
02:40 PM
[Ransomware] Taking the Mystery out of Ransomware
Dec 07, 2016
Lost data. Systems locked down. Whole companies coming to a grinding halt. When it comes to ransom ...Read More>>

Online Data Instead Of Drug Retrials?

When aggregated, unstructured data from online forums for patients can reveal problems with drugs--but right now, regulators aren't accepting such data.

Unstructured data culled from online patient discussion forums and other social media is emerging as a way to identify problems with new drugs. Patients on social sites frequently compare notes on suspected side effects of drugs. When aggregated, this data can reveal suspect drugs. But the data and analysis aren't useful as long as regulators refuse to accept them as part of post-market research.

Currently, when a drug that's already on the market is suspected of not performing as promised or of causing dangerous side effects, the Food and Drug Administration requires that data to be submitted in formal reporting forms. Unstructured data pulled from patients' online discussions isn't acceptable, no matter how much of it exists.

"This is a science still in its infancy," said Dr. Roni Zeiger, Google's chief health strategist, speaking at Partners Healthcare's Connected Health Symposium last month. While it isn't clear exactly how unstructured data could be leveraged, its potential value is significant, Zeiger said. We need "large-scale methods" of monitoring online data that don't involve actual human monitoring but rather algorithms that identify the information that's useful to researchers, he said.

The FDA must look at the potential for new sources of surveillance data and come up with clinical research policies that take into account all emerging sources of patient- and consumer-related health data, Zeiger said.

Retrial Alternative

False positives are the biggest issue with unstructured data, such as when a patient thinks he's having an unusual side effect from a medication but it's actually not a reaction to the drug at all.

The structured data forms that the FDA accepts now have their own problems. For one, few patients and doctors ever use them. "I've yet to fill out an adverse event report on the FDA site," said Zeiger, who has been a practicing physician for nearly a decade.

And once the FDA has collected evidence of a problem, it then requires lengthy, expensive clinical retrials of the drug. "That's too expensive a methodology," Jay Pieper, VP of Partners Healthcare and president and CEO of Partners International Medical Services, said at the symposium. Retrials can cost drugmakers tens of millions of dollars.

Data generated on social media combined with analytics tools that would help weed out problems like false positives could provide new opportunities to take action on problem drugs without retrials, Pieper said.

Comment  | 
Print  | 
More Insights
Newest First  |  Oldest First  |  Threaded View
How Enterprises Are Attacking the IT Security Enterprise
How Enterprises Are Attacking the IT Security Enterprise
To learn more about what organizations are doing to tackle attacks and threats we surveyed a group of 300 IT and infosec professionals to find out what their biggest IT security challenges are and what they're doing to defend against today's threats. Download the report to see what they're saying.
Register for InformationWeek Newsletters
White Papers
Current Issue
Top IT Trends to Watch in Financial Services
IT pros at banks, investment houses, insurance companies, and other financial services organizations are focused on a range of issues, from peer-to-peer lending to cybersecurity to performance, agility, and compliance. It all matters.
Twitter Feed
InformationWeek Radio
Archived InformationWeek Radio
Join us for a roundup of the top stories on for the week of November 6, 2016. We'll be talking with the editors and correspondents who brought you the top stories of the week to get the "story behind the story."
Sponsored Live Streaming Video
Everything You've Been Told About Mobility Is Wrong
Attend this video symposium with Sean Wisdom, Global Director of Mobility Solutions, and learn about how you can harness powerful new products to mobilize your business potential.
Flash Poll